Rasmus Blechingberg Friis

The ProWide study has finally been published. In a Danish population, remote ePRO-based symptom monitoring does not improve survival for patients with #lungcancer. Should we reevaluate the expected clinical benefits of ePROs? @JCOOP_ASCO ascopubs.org/doi/10.1200/OP… @cancer_dk

Find me on bsky.app/profile/rbfrii… #twitterisdead

Editorial comments on the ProWide study. I agree that clinical use of ePROs offers several important benefits beyond overall survival. #lungcancer ascopubs.org/doi/10.1200/OP…

Danish Melanoma Lifetime Achievement Award to Lars Bastholt - Danish Metastatic Melanoma Database @RuhlmannC @DoniaMarco @Rbfriis oncodaily.com/blog/danish-me… #Cancer #OncoDaily #MedEd #MedX #MedNews #Medicine #Oncology #DAMMED

Great presentation at the annual Danish Melanoma Scientific Meeting by @OlofssonBagge about present and future surgical treatment of advanced melanoma

I don't think I've ever worked this hard on anything in my career. The initial work for this study started back in 2016. Despite legal challenges with digital health data and the COVID-19 lockdown, we succeeded with a tremendous collaboratory effort in this Danish national RCT 🙂

Man bør anerkende, at der er områder, hvor mænd er særligt udsatte. Ligestillingen halter, når det for eksempel kommer til mænds mentale sundhed. Det har jeg skrevet om sammen med @SamiraNawa og en række aktører på området. #dkpol #sundpol socialmonitor.dk/debat/art10200…

@EthanBasch1 @Helle_PP @lisa_wintner @EORTC_QLG @madeline_pe @OncoAlert @OncBrothers @OncLive @VJOncology

@EthanBasch1 @Helle_PP @lisa_wintner @EORTC_QLG @madeline_pe @OncoAlert @OncBrothers @OncLive @VJOncology

The ProWide study has finally been published. In a Danish population, remote ePRO-based symptom monitoring does not improve survival for patients with #lungcancer. Should we reevaluate the expected clinical benefits of ePROs? @JCOOP_ASCO ascopubs.org/doi/10.1200/OP… @cancer_dk

@RyanNipp @ASCO @JCO_ASCO @JCOOP_ASCO Thanks for sharing :-)

Remote Symptom Monitoring of Patients With Advanced Lung #Cancer (The ProWide Study): A Randomized Controlled Trial. ascopubs.org/doi/10.1200/OP… @ASCO @JCO_ASCO @JCOOP_ASCO #LungCancer #PallOnc #SuppOnc

@oncology_bg Does DMFS correlate with OS in an adjuvant setting for pts with melanoma?

What questions can you think of regarding surrogate endpoints in oncology? We try to answer them all in this review. This is open access. So feel free to download, circulate, and use it as a teaching and discussion tool. thelancet.com/journals/eclin… All the following questions are answered in this review. Did we miss any other question? 1. How are various surrogate endpoints defined? 2. How are surrogate endpoints validated? 3. What is the difference between patient-level surrogate and trial-level surrogate? 4. What are the potential benefits of using surrogate endpoints? 5. What strength of surrogacy is required for accelerated versus regular approval? 6. Are we overusing and over-relying on surrogates for regulatory approvals? 7. Should we consider surrogate endpoints differently in the adjuvant setting? 8. can we extrapolate validity of surrogate endpoints from one setting to another? 9. What is the strength of correlation for PFS, the most commonly used surrogate endpoint in trials of advanced cancer? 10. Why does PFS not corelate with OS? 11. Does PFS correlate with quality of life? 12. Do patients and public understand PFS correctly? 13.Why do regulators continue to rely on PFS? 14. What is the way forward? 15. If the endpoint is OS or validated surrogate, can we be confident in the results?

This is one of the greatest achievements in the history of cancer treatment. #melanoma #immunotherapy #esmo24 #cure

@HildurHelg presents out Swedish data showing no OS benefit with adjuvant immunotherapy for stage III melanoma. #ESMO24

#ESMO24: Questions remain on optimal #AdjuvantTherapy for advanced #melanoma. OS trial data are not yet available & #RealWorld data suggest that surrogate endpoints may not translate into OS benefit in clinical practice @TeresaSAmaral #ESMODailyReporter 📌ow.ly/51Cs50TnILV

Bravo! @ciccarese_c - beautiful presentation. Congrats to you, @DrIacovelli & the stellar team on intriguing data - a hugely important contribution to the emerging data on #microbiome modulation. Looking fwd to seeing next steps! #ESMO24

@DrIacovelli @weoncologists @ciccarese_c @gianluca1aniro @OncoAlert @Unicatt @nsegata @CPRT65 @ChristianHvas

@ciccarese_c rocked the stage presenting preliminary data of TACITO trial investigating #FMT on #mRCC. Primary endpoint 1-y PFS met and no safety issues. Thanks to @gianluca1aniro leading the gastroenterology team & all coinvesigators for this significant achievement. @OncoAlert

Looking forward to #ESMO24 🙂

@matteolambe @AnnPartridgeMD @DanaFarber @myESMO @OncoAlert @YSCBuzz @TanjaSpanic What a wonderful presentation :-)

One the most awaited moment for me at this #ESMO24….the best of best @AnnPartridgeMD from @DanaFarber receiving @myESMO award during the opening ceremony for her incredible efforts in improving the care of #BreastCancer in young women ❤️ @OncoAlert @YSCBuzz @TanjaSpanic

@ADMoller Hvad nu? Jeg kan ikke læse det. Jeg ved ikke om jeg orker flere politiske "nu viser jeg handlekraft-projekter"

Cardiotoxicity of Immune Checkpoint Inhibitors jamanetwork.com/journals/jamao…